Genesis COVID-19 Treatment Infusion Center
Clinical trials have shown that monoclonal antibodies are effective in treating COVID 19. Lilly, in partnership with AbCellara, has developed a monoclonal antibody called bamlanivimab. Bamlanivimab is a recombinant neutralizing human IgG1 monoclonal antibody directed against the spike protein of SARS-CoV-2. It is designed to block viral attachment and entry into human cells, thus neutralizing the virus. Bamlanivimab must be administered by intravenous (IV) infusion.